Chemical Structure (Pregabalin 01)
Chemical structure of pregabalin, showing its molecular arrangement with carboxyl, amino groups, and carbon backbone.*
Pregabalin Capsule
Product Images NDC 71205-733
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-733). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Pregabalin 02)
A line graph depicting percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, showing patient improvement trends across increasing pain relief percentages.*
Figure 2 (Pregabalin 03)
A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. Two lines represent Pregabalin 100 mg three times a day and placebo. The graph shows a higher percentage of patients improved with Pregabalin across increasing levels of pain improvement from 0% to 100%.*
Figure 3 (Pregabalin 04)
Line graph showing percent of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. The graph compares Pregabalin doses of 75 mg, 150 mg, and 300 mg taken two times a day against placebo, illustrating varying levels of patient improvement in pain symptoms.*
Figure 4 (Pregabalin 05)
A line graph displaying the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day (solid line), Pregabalin 100 mg three times a day (dashed line), and Placebo (dotted line), illustrating pain improvement distributions across different thresholds.*
Figure 5 (Pregabalin 06)
A line graph comparing percent of patients improved versus percent improvement in pain from baseline. It shows three lines for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating patient response to these treatments.*
Figure 6 (Pregabalin 07)
A bar chart illustrating responder rates (%) from two clinical studies labeled Study E1 and Study E3. The x-axis shows different treatment groups including placebo and various daily dosages of Pregabalin (50 mg/day to 600 mg/day). The y-axis represents responder rates ranging from 0% to 60%. Study E1 presents gradual increases in responder rates with higher Pregabalin doses, peaking at 51% for 600 mg/day. Study E3 shows responder rates for placebo, 300 mg/day (BID), and 600 mg/day (TID) with values up to 49% at 600 mg/day.*
Figure 7 (Pregabalin 08)
This figure depicts a line graph showing seizure reduction as median percent change from baseline versus dose (mg/day) for Pregabalin across four different studies with dosing regimens BID and TID. Data points indicate increasing seizure reduction with higher doses, with significant p-values noted for all compared doses to placebo (0 dose).*
Figure 9 (Pregabalin 09)
A Kaplan-Meier curve chart depicting percent of patients improved over percent improvement in pain from baseline. The chart compares four groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo. The vertical axis shows the percent of patients improved from 0 to 100%, while the horizontal axis shows percent improvement in pain from baseline ranging from 0 to 100%, with vertical reference lines at 30% and 50% improvement.*
Figure 10 (Pregabalin 10)
A survival curve chart comparing the estimated percentage of subjects without LTR over time in days for Pregabalin versus placebo. The Y-axis shows the estimated percentage of subjects without LTR, ranging from 0% to 100%, and the X-axis shows the duration in days from 0 to 180. The solid line represents Pregabalin, showing a higher percentage of subjects without LTR over time compared to the dashed line representing placebo.*
Figure 11 (Pregabalin 11)
A line graph comparing the percent of subjects improved from baseline to Week 12 using BOCF method for Pregabalin versus Placebo. The x-axis shows percent improvement, ranging from >0 to 100, and the y-axis shows the percent of subjects improved, from 0 to 100. Pregabalin displays a higher percentage of subject improvement compared to Placebo throughout the range.*
Figure 12 (Pregabalin 12)
A line graph comparing the percentage of subjects improved over time from baseline to week 16, showing data for Pregabalin versus Placebo. The x-axis represents the percent improved from baseline to week 16 BOCF, ranging from greater than 0 to 100. The y-axis shows the percent of subjects improved, from 0% to 100%. Two lines depict outcomes, with Pregabalin showing consistently higher improvement percentages than Placebo.*
71205-733-60 (Pregabalin 13)
Label for Pregabalin 25 mg capsules by Proficient Rx LP, containing 60 capsules. The label indicates each capsule contains 25 mg pregabalin and describes the capsule appearance as white to off-white powder in size 4 hard gelatin capsules with white opaque cap and body, printed 'SG' and '350' in black ink. The label includes storage instructions at 25°C and manufacturer details: ScieGen Pharmaceuticals, Inc., Hauppauge, NY.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
